请提供关键要点内容。

公司概况 - 公司目前拥有两个授权平台:一个是通用药品组合,另一个是生物类似物生物制品平台,用于治疗癌症[122] - 公司还拥有两项专有专利技术,包括黑色素细胞受体结合分子和基因疗法平台,使用基因疗法方法将一种称为"Klotho"的治疗蛋白引入体内,以治疗神经退行性疾病[122] - 公司于2024年6月21日完成与Redwoods Acquisition Corp.的业务合并,Redwoods更名为"ANEW Medical, Inc."[123] 财务状况 - 公司2024年上半年的运营费用为817,652美元,较2023年上半年的396,852美元增加了420,800美元,增幅约为106%,主要是由于为业务合并做准备而增加了第三方咨询费和专业费用[129] - 公司2024年上半年的净亏损为1,123,683美元,较2023年上半年的436,872美元增加了686,811美元,增幅约为157%,主要原因同上[131] - 公司2024年6月30日的现金余额为845,336美元,但存在持续经营的重大不确定性,需要通过股权或债务融资来获得更多运营资金[137,139] 公司地位 - 公司目前为新兴成长公司,可以享受相关豁免政策,但一旦不再符合条件,可能会对公司股票的吸引力产生不利影响[141,143]

文章核心观点 - 公司ANEW MEDICAL, INC.("ANEW")正式在纳斯达克全球市场上市,股票代码为"WENA",认股权证代码为"WENAW" [1][3] - ANEW是一家专注于神经系统和老龄相关疾病诊断和新型治疗方法研发的专科制药公司 [2][4] - 公司创始人兼CEO Joseph Sinkule博士表示,ANEW拥有一支经验丰富的管理团队,正在开发多项平台技术和产品候选药物,并将在未来一年内宣布重要里程碑 [3] - ANEW通过此次交易将更加专注于核心业务,并制定行业特定的增长和市场策略,实现战略性资本配置 [3] 公司概况 - ANEW专注于神经系统和老龄相关疾病如阿尔茨海默病、痴呆症状和神经肌肉疾病的诊断和新型治疗方法研发,拥有独家开发和商业化秘钥基因Klotho蛋白相关产品的权利 [4] - 公司正在评估其他核心技术平台,以进行开发和商业化 [4] 投资亮点 - ANEW拥有经验丰富的管理团队,正在开发多项平台技术和产品候选药物,并将在未来一年内宣布重要里程碑 [3] - 公司通过此次交易将更加专注于核心业务,并制定行业特定的增长和市场策略,实现战略性资本配置 [3]

ANEW MEDICAL, INC.'s shares and warrants are expected to begin trading on the Nasdaq Global Market under the tickers "WENA" and "WENAW", respectively.  NEW YORK, NY, June 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company"), a biopharmaceutical technology company focused on developing disruptive new therapies to treat the central nervous system ("CNS") and neurodegenerative diseases, and Redwoods Acquisition Corp. (NASDAQ: RWOD) ("RWOD"), a publicly-traded special purpose acquisition co ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001-41340 REDWOODS ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (Sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41340 Redwoods Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (State or other jurisdiction o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ________________ Commission file number: 001-41340 REDWOODS ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 86-2727441 (Sta ...